Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Agosto 2024 - 10:10PM
Business Wire
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunological diseases, granted stock options to purchase
29,150 shares of Astria’s common stock on August 1, 2024 under
Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement
Stock Incentive Plan is used exclusively for the grant of equity
awards to individuals who were not previously an employee of
Astria.
The options were granted as an inducement material to two
employees entering into employment with Astria in accordance with
Nasdaq Listing Rule 5635(c)(4). The options have an exercise price
of $11.19, which is equal to the closing price of Astria’s common
stock on August 1, 2024 (the “Grant Date”), and will vest over a
four-year period, with 25% of shares vesting on the first
anniversary of the employee’s employment start date (which preceded
the Grant Date) and the remaining shares vesting monthly on a
ratable basis over the following 36 months, subject to the
employee’s continued employment with Astria on such vesting dates.
The options are subject to the terms and conditions of the 2022
Inducement Stock Incentive Plan and the terms and conditions of an
award agreement covering the grant.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by allergic and immunological diseases. Our lead
program, STAR-0215, is a monoclonal antibody inhibitor of plasma
kallikrein in clinical development for the treatment of hereditary
angioedema. Our second program, STAR-0310, is a monoclonal antibody
OX40 antagonist in preclinical development for the treatment of
atopic dermatitis. Learn more about our company on our website,
www.astriatx.com, or follow us on X and Instagram @AstriaTx and on
Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240802889453/en/
Investor Relations and Media: Elizabeth Higgins
investors@astriatx.com
Grafico Azioni Astria Therapeutics (NASDAQ:ATXS)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Astria Therapeutics (NASDAQ:ATXS)
Storico
Da Gen 2024 a Gen 2025